Greenwood Capital Associates LLC Has $8.65 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Greenwood Capital Associates LLC raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 23.2% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 13,873 shares of the biopharmaceutical company’s stock after acquiring an additional 2,612 shares during the period. Regeneron Pharmaceuticals comprises about 0.9% of Greenwood Capital Associates LLC’s investment portfolio, making the stock its 27th largest holding. Greenwood Capital Associates LLC’s holdings in Regeneron Pharmaceuticals were worth $8,650,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Orbimed Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at $11,358,000. Lockheed Martin Investment Management Co. acquired a new position in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $2,702,000. BlackRock Inc. acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth $5,682,636,000. National Pension Service raised its position in shares of Regeneron Pharmaceuticals by 29.8% during the 4th quarter. National Pension Service now owns 360,988 shares of the biopharmaceutical company’s stock valued at $278,636,000 after acquiring an additional 82,853 shares during the last quarter. Finally, Eurizon Capital SGR S.p.A. acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $10,472,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Trading Down 1.7%

NASDAQ REGN opened at $794.19 on Friday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $541.00 and a 52 week high of $847.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. The stock’s 50 day moving average price is $717.52 and its two-hundred day moving average price is $718.38. The stock has a market capitalization of $81.77 billion, a price-to-earnings ratio of 19.63, a PEG ratio of 1.35 and a beta of 0.22.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. The business had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $12.81 earnings per share. As a group, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Tuesday, August 18th will be given a $0.94 dividend. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is currently 9.29%.

Analysts Set New Price Targets

REGN has been the topic of several analyst reports. Leerink Partners increased their target price on Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the company a “market perform” rating in a research note on Monday, August 17th. Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, June 24th. Guggenheim boosted their price target on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Morgan Stanley lifted their target price on Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the stock an “equal weight” rating in a report on Friday, July 31st. Finally, Truist Financial increased their price target on Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Fifteen investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $800.36.

Insider Buying and Selling

In related news, Director Huda Y. Zoghbi sold 800 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the completion of the transaction, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. This represents a 31.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $320,000.00. Following the transaction, the director directly owned 603 shares in the company, valued at $482,400. This trade represents a 39.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 1,400 shares of company stock worth $1,090,030. Corporate insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: The FDA approved Pasatru (garetosmab) for adults with fibrodysplasia ossificans progressiva, an ultra-rare genetic disorder that causes abnormal bone growth. In a 56-week Phase 3 trial, the approved dose reduced disease-related bone formation, giving Regeneron a new commercial opportunity and strengthening its rare-disease pipeline. However, the small patient population likely limits the drug’s near-term earnings contribution. Can Regeneron’s Rare-Disease Win Move the Earnings Needle?
• Neutral Sentiment: An investor letter highlighted Regeneron’s response to mixed results from its melanoma drug trials, including adjustments to its development strategy. The update offers limited new information but underscores the importance of replacing potential value lost from the failed program. Regeneron Adjusts Course Amid Mixed Results in Melanoma Drug Trials
• Negative Sentiment: Several law firms announced or promoted a securities-fraud class action related to disclosures surrounding Regeneron’s failed Phase 3 melanoma trial. The failure reportedly erased approximately $11 billion in market capitalization and prompted allegations that investors were misled about the program. The repeated notices, all citing a September 14, 2026 lead-plaintiff deadline, add reputational and potential litigation-cost risks, although they do not represent a finding of wrongdoing. Regeneron Securities Fraud Class Action Filed Faruqi Shareholder Notice

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.